TNGX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
-100.0%
53.8M
+1591.6%
3.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
-100.0%
53.8M
+1591.6%
3.2M
Operating Expenses
59.8M
+22.6%
48.8M
+16.5%
41.9M
+5.3%
39.7M
-10.0%
44.1M
R&D
37.2M
+10.9%
33.5M
+4.5%
32.1M
+4.2%
30.8M
-6.1%
32.8M
SG&A
22.6M
+48.3%
15.2M
+56.0%
9.8M
+9.4%
8.9M
-21.3%
11.3M
Operating Income
-59785000
-22.6%
-48769000
-16.5%
-41864000
-397.5%
14.1M
+134.3%
-40967000
EBITDA
-59360000
-22.9%
-48306000
-16.7%
-41385000
-382.9%
14.6M
+136.3%
-40342000
Net Income
-55341000
-21.6%
-45514000
-17.5%
-38749000
-343.9%
15.9M
+140.9%
-38853000
EPS (Basic)
$-0.37
-15.6%
$-0.32
-10.3%
$-0.29
-307.1%
$0.14
+140.0%
$-0.35
EPS (Diluted)
$-0.37
-15.6%
$-0.32
-3.2%
$-0.31
-338.5%
$0.13
+137.1%
$-0.35
Shares (Diluted)
149.9M
+4.4%
143.6M
+13.9%
126.0M
+7.0%
117.8M
+6.6%
110.5M
Tango Therapeutics (TNGX) โ€” Financials